Use of Construal Level Theory to Inform Messaging to Increase Vaccination Against COVID-19
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 3,671
- 试验地点
- 2
- 主要终点
- Number of Participants Who Received a Booster Vaccination Through the Targeted Visit
研究概览
简要总结
This study aims to increase uptake of the COVID booster vaccine through messaging informed by Construal Level Theory. Patients in the Mass General Brigham (MGB) health system aged 18 and older who are eligible for the COVID booster vaccine, but who have not yet received a dose at the time of an upcoming primary care clinic visit, will be randomized to one of three messaging arms: 1) "why" messaging, 2) "how" messaging, or 3) standard of care ("usual care"). Messages will be sent via the electronic patient portal a few days in advance of their office visit. The primary outcome will be the rate of booster vaccination at the targeted visit. The secondary outcome will be the rate of receipt of a COVID booster vaccine within 6 weeks of the targeted visit. Subgroup analyses to assess for any association of patient characteristics with intervention responsiveness will be exploratory.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Health Services Research
- 盲法
- Single (Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients in the Mass General Brigham system
- •Aged 18 and older
- •Are eligible for the COVID booster vaccine but have not received a dose at time of upcoming primary care clinic visit
排除标准
- •Documented allergy to a COVID vaccine or its components
- •Home address outside of Massachusetts
- •Did not receive full set of primary COVID-19 vaccination series
结局指标
主要结局
Number of Participants Who Received a Booster Vaccination Through the Targeted Visit
时间窗: 2-5 days
Number of participants who received one dose of a COVID booster vaccine between randomization through the date of the scheduled visit, determined through electronic health records.
次要结局
- Number of Participants Who Received a Booster Vaccination Within 6 Weeks of the Targeted Visit(6 weeks after the target visit)
研究者
Nancy Haff, MD, MPH
Associate Epidemiologist, Division of Pharmacoepidemiology
Brigham and Women's Hospital
